11/19
03:58 pm
imcr
FATE Presents Encourgaing Data From Lupus Study, Stock Gains [Yahoo! Finance]
Low
Report
FATE Presents Encourgaing Data From Lupus Study, Stock Gains [Yahoo! Finance]
11/19
09:14 am
imcr
Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
Medium
Report
Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
11/13
01:26 pm
imcr
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus [Yahoo! Finance]
Low
Report
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus [Yahoo! Finance]
11/11
07:47 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $38.00 price target on the stock, down previously from $72.00.
Medium
Report
Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $38.00 price target on the stock, down previously from $72.00.
11/8
09:00 am
imcr
The Galien Foundation Honors 2024 Prix Galien Award Recipients
Medium
Report
The Galien Foundation Honors 2024 Prix Galien Award Recipients
11/8
07:00 am
imcr
Immunocore to present at upcoming investor conferences
Low
Report
Immunocore to present at upcoming investor conferences
11/7
08:36 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $78.00 to $71.00. They now have a "buy" rating on the stock.
Medium
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $78.00 to $71.00. They now have a "buy" rating on the stock.
11/6
07:00 am
imcr
Immunocore reports third quarter financial results and provides a business update
Low
Report
Immunocore reports third quarter financial results and provides a business update
11/5
02:02 pm
imcr
Immunocore (IMCR) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
Immunocore (IMCR) Upgraded to Buy: Here's Why [Yahoo! Finance]
10/24
08:08 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
10/24
07:16 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) is now covered by analysts at UBS Group AG. They set a "sell" rating and a $24.00 price target on the stock.
Medium
Report
Immunocore Holdings plc (NASDAQ: IMCR) is now covered by analysts at UBS Group AG. They set a "sell" rating and a $24.00 price target on the stock.
10/21
09:56 am
imcr
DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications
Medium
Report
DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications
10/11
12:46 pm
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Morgan Stanley from $80.00 to $74.00. They now have an "overweight" rating on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Morgan Stanley from $80.00 to $74.00. They now have an "overweight" rating on the stock.
10/7
09:10 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
10/7
07:00 am
imcr
Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board
Low
Report
Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board
9/17
08:02 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
9/17
08:02 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $81.00 to $78.00. They now have a "buy" rating on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $81.00 to $78.00. They now have a "buy" rating on the stock.
9/14
03:00 am
imcr
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Low
Report
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
9/12
04:05 pm
imcr
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Low
Report
Immunocore to present at the 2024 Cantor Global Healthcare Conference
9/9
02:14 pm
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/3
05:46 pm
imcr
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight
Low
Report
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight
9/3
05:46 pm
imcr
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight
Low
Report
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight
8/30
01:38 pm
imcr
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak [Seeking Alpha]
Low
Report
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak [Seeking Alpha]
8/29
08:38 am
imcr
Immunocore CFO to leave company [Seeking Alpha]
Medium
Report
Immunocore CFO to leave company [Seeking Alpha]
8/29
07:00 am
imcr
Immunocore announces transition of Chief Financial Officer
Medium
Report
Immunocore announces transition of Chief Financial Officer